Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

NCT02530463 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

99

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndrome
Recurrent Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]